Facts and figures

products icon

29.2 million patients use our diabetes products

products icon

Our products are marketed in 170 countries

affiliates icon

We have affiliates in 80 countries

Our products

Main product areas

Growth disorders
Hormone replacement therapy

Our products



Annual sale 2018

111,831 million Danish kroner?

Q1 2019

29,291 million Danish kroner

First-quarter results for 2019


Sales by region
Q1 2019

North America Operations

13,904 million Danish kroner

USA:?13,211 million Danish kroner

Canada: 693 million Danish kroner


International Operations

15,387 million Danish kroner

Region Europe:?5,505 million Danish kroner

Region AAMEO: 3,738 million Danish kroner

Region China: 3,375 million Danish kroner

Region Japan & Korea:?1,458 million Danish kroner

Region Latin America: 1,311 million Danish kroner


Sales by business segment
Q1 2019

Diabetes and obesity care total

24,818 million Danish kroner


Biopharmaceuticals total

4,473 million Danish kroner



research icon

We invest 13.2% of sales in R&D

employee icon

19% of our global workforce works within R&D

research icon

We have R&D centres in China, Denmark, India, UK and US

Our research focus


All people diagnosed with diabetes should receive treatment

Learn more about our access and affordability activities

Graphic: Insulin vials

In 2018,?5 million?people with diabetes were treated with our human insulin at a maximum of 4 USD per 10ml vial

Graphic: Children

Our Changing Diabetes in Children? programme has provided treatment to 19,000+ children with type 1 diabetes

Graphic: Donations

In 2018, we donated?85 million?Danish kroner to the World Diabetes Foundation


Number of employees

Approximately 42,400 full time employees (FTEs) March 2019.

Business area distribution

19% within research and development

32% in production and production administration

37% in international sales and marketing

12% in administration

Novo Nordisk employees angaging

Affiliate distribution (FTEs as of March 2019)

Approximately 40% of employees are located in Denmark (16,789 FTEs) and 60% in the rest of the world:

Africa, Asia, Middle East & Oceania: 7,217 FTEs

China & Taiwan: 4,646 FTEs

Denmark: 16,789 FTEs

Europe (excl. HQ): 4,582 FTEs

Japan (994) & Korea: 1,140 FTEs

Latin America: 1,982 FTEs

North America (US 5,781 & Canada 316): 6,097 FTEs

(includes Novo Nordisk and NNE employees)



affiliates icon

We supply nearly half the world's insulin


Clean energy icon

By 2020 all our production will run on 100% renewable power

research icon

We have production sites in Brazil, China, Denmark, France and the US


We are located in Denmark

Novo Nordisk A/S
Novo Allé 1
2880 Bagsv?rd
CVR nr. 24 25 67 90

Contact us